Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Significant Decrease in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) saw a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 266,500 shares, a drop of 64.8% from the January 15th total of 757,800 shares. Currently, 1.6% of the shares of the company are short sold. Based on an average daily volume of 454,900 shares, the short-interest ratio is presently 0.6 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. National Bank of Canada FI increased its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 45,575 shares of the company’s stock after buying an additional 35,575 shares during the period. National Bank of Canada FI owned 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Stock Performance

Shares of SNSE stock traded down $0.00 on Wednesday, hitting $0.47. The company had a trading volume of 37,513 shares, compared to its average volume of 592,431. The stock’s 50-day moving average is $0.49 and its two-hundred day moving average is $0.53. The firm has a market cap of $11.82 million, a P/E ratio of -0.39 and a beta of 0.17. Sensei Biotherapeutics has a twelve month low of $0.38 and a twelve month high of $1.94.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Sensei Biotherapeutics in a report on Wednesday, January 8th.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.